LYPLA2

Across TCGA pan-cancer cohorts, LYPLA2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LYPLA2 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher LYPLA2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LYPLA2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

PRAD, COAD, and SKCM are the cancer types where LYPLA2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	DFS	Median	All	0.223	0.690	.009	6	view →
SKCM	OS	Median	All	0.310	0.786	.029	3	view →
UCEC	DFS	Median	All	1.000	0.625	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LYPLA2–PRAD (DFS)

Open the PRAD breakdown →